Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
Background: Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publishing
2023-11-01
|
| Серии: | Therapeutic Advances in Chronic Disease |
| Online-ссылка: | https://doi.org/10.1177/20406223231213251 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|